Mr. Alejandro Antalich reports

EVOKAI CREATIVE LABS FILES FINAL BASE SHELF PROSPECTUS

EvokAI Creative Labs Inc. has filed a final short form base shelf prospectus with the securities regulatory authorities in each of the provinces and territories of Canada (other than Quebec), following the completion of a regulatory review.

The shelf prospectus will permit the company to make offerings of common shares, warrants, subscription receipts, units or debt securities, or a combination thereof, up to an aggregate total of $125-million during the 25-month period that the shelf prospectus remains effective until November, 2025. Securities may be offered in amounts, at prices and on terms to be determined based on market conditions at the time of sale and set forth in one or more shelf prospectus supplements. Information regarding the use of proceeds from the sale of any securities will be included in the applicable prospectus supplements.

A copy of the shelf prospectus is available on the company's issuer profile on SEDAR+ and may also be obtained by contacting the corporate secretary of the company by e-mail at hello@evokailabs.com.

About EvokAI Creative Labs Inc.

EvokAI is a medtech artificial-intelligence-powered company dedicated to the development of transformational and innovative technologies for the modern health care sector. It deploys machine learning models to search medical data and uncover insights to help improve health outcomes, patient experiences, drug development, preclinical and clinical decisions, and provide more accurate diagnoses. EvokAI tailors its AI algorithms across the whole health care system from hospitals, private clinics, research institutions, pharmaceutical companies and contract research organizations to medical professionals, patients and healthy individuals, aiming at preventing any kind of disease and beyond, protecting the aging genome.

We seek Safe Harbor.